Reaction
Pancreatic Carcinoma Recurrent reporting signals
As of the last recalculation, Pancreatic Carcinoma Recurrent appears in 234 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 202.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pancrelipase | 64 | 202.6 | 203.0 |
| Gemcitabine | 24 | 60.3 | 60.3 |
| Gemcitabine Hydrochloride | 27 | 51.0 | 51.1 |
| Irinotecan Hydrochloride | 6 | 42.6 | 42.6 |
| Olaparib | 8 | 35.2 | 35.2 |